SecBot SecBot
PRESS-RELEASE ·Filed Mar 4, 2026

OCGN

Ocugen
MIXED
Impact 6/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

Investors should monitor the full Phase 2 OCU410 data in March 2026 and upcoming clinical milestones as potential catalysts. The cash runway remains tight, but dilution risk may be mitigated if Janus Henderson warrants are exercised. Positive data could drive re-rating despite current losses.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.96
T+0 close · Mar 4, 2026 · via day close
Latest settled
−28.06%
T+60 · $1.41
Vs SPY
−38.15%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 4 $1.96entry
  2. T+1 · 9mo ago −11.22%α −10.65% · $1.74
  3. T+5 · 8mo ago +17.35%α +18.68% · $2.30
  4. T+20 · 8mo ago −8.67%α −4.26% · $1.79
  5. T+60 · 6mo ago −28.06%α −38.15% · $1.41
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ocugen reported Q4 and full-year 2025 financial results showing increased R&D spending and a wider net loss, while highlighting clinical progress across its gene therapy pipeline, including completed Phase 3 enrollment for OCU400 and positive preliminary Phase 2 data for OCU410 in geographic atrophy. The company extended its cash runway into Q4 2026 via a $22.5M financing, with potential extension to Q2 2027 if warrants are exercised.

Key Financial Metrics

Revenue
-$193.0K
-125.2% YoY
EPS
$-0.06

Key Facts

  • Completed enrollment in OCU400 Phase 3 trial for retinitis pigmentosa; topline data expected Q1 2027.
  • Positive preliminary Phase 2 data for OCU410 in geographic atrophy: 46% lesion growth reduction (p=0.015), 50% responder rate with >50% reduction.
  • OCU410ST Phase 2/3 trial for Stargardt disease nearing enrollment completion; interim data expected Q3 2026.
  • Secured $22.5M in gross proceeds in January 2026; cash runway extended to Q4 2026, potentially Q2 2027 with full warrant exercise.
  • Cash and restricted cash: $18.9M as of Dec 31, 2025, down from $58.8M a year prior.
  • Net loss per share increased to $0.06 (Q4) and $0.23 (full year) from $0.05 and $0.20 respectively in 2024.

Financial Impact

Revenue declined to -$193K in Q4 2025 from $764K in Q4 2024; full-year revenue increased slightly to $4.4M. Net loss widened to $67.8M in 2025 from $54.1M in 2024. R&D expenses rose to $39.8M from $32.1M.

revenuenet_lossr_and_d_expensecash

Risk Factors

  • Clinical trial results may not meet expectations, particularly in Phase 3 for OCU400 and upcoming OCU410 readouts.
  • Cash runway remains limited; additional financing may lead to further dilution.
  • No revenue from product sales; company remains pre-commercial with high R&D burn.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3249353

Track record

23 reports on OCGN

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +20.49% at T+20 after the Jun 11, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
  2. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
  3. Nov 6, 202610d ago DEFA14A Neutral 2/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
  4. Nov 6, 202610d ago DEFA14A Neutral 3/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
  5. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $0.8745 to $0.8165 Now $0.7730 −11.61% ▼ −6.63% −2.22% vs SPY
  7. Oct 15, 20264w ago 8-K Neutral 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
  8. Oct 14, 20264w ago 8-K Mixed 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
  9. Oct 9, 20265w ago 144 Neutral 2/10 Entry $0.9472 to $0.8854 Now $0.7730 −18.39% ▼ −6.52% −6.51% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 7/10 Entry $1.33 to $1.32 Now $0.7730 −41.88% ▼ −0.75% −1.20% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 4, 2026